<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Patency definitions following hemodialysis access intervention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Patency definitions following hemodialysis access intervention</h1>
<div class="graphic"><div class="figure"><div class="ttl">Patency definitions following hemodialysis access intervention</div><div class="cntnt"><table cellspacing="0"><colgroup width="100%"></colgroup> <tbody> <tr> <td class="subtitle1_single">Access primary patency</td> </tr> <tr class="divider_bottom"> <td class="indent1">Interval of time from <span style="font-size: 11pt; font-family: 'Calibri',sans-serif;">AV dialysis access creation to the ﬁrst of one of the following events: access thrombosis; any intervention designed to facilitate, maintain, or re-establish patency; the access reaches a censoring event as speciﬁed <em>a priori </em>in the study protocol; or study end.</span></td> </tr> <tr> <td class="subtitle1_single">Access assisted primary patency</td> </tr> <tr class="divider_bottom"> <td class="indent1">Interval of time from AV dialysis access creation until the first of one of the following events: <span style="font-size: 11pt; font-family: 'Calibri',sans-serif;">access thrombosis, the access reaches a censoring event as speciﬁed <em>a priori </em>in the study protocol, or study end. This period includes all intervening interventions (surgical or endovascular) designed to maintain the functionality of the dialysis vascular access as long as patency is not lost.</span></td> </tr> <tr> <td class="subtitle1_single">Access cumulative patency*</td> </tr> <tr class="divider_bottom"> <td class="indent1">Interval of time from AV dialysis access creation until access abandonment, the access reaches a censoring event as specified <em>a priori</em> in the study protocol, or study end, including intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of the access.</td> </tr> <tr> <td class="subtitle1_single">Post-intervention<sup>¶</sup> primary patency</td> </tr> <tr class="divider_bottom"> <td class="indent1">The interval of time from the index IDBD until the <span style="font-size: 11pt; font-family: 'Calibri',sans-serif;">ﬁrst of one of the following events: access thrombosis; any intervention designed to facilitate, maintain, or re-establish patency; the access reaches a censoring event as speciﬁed <em>a priori </em>in the study protocol; or study end.</span></td> </tr> <tr> <td class="subtitle1_single">Post-intervention<sup>¶</sup> assisted primary patency</td> </tr> <tr class="divider_bottom"> <td class="indent1">The interval of time <span style="font-size: 11pt; font-family: 'Calibri',sans-serif;">from the index IDBD intervention to the ﬁrst of one of the following events: access thrombosis, a surgical intervention that excludes the treated lesion from the dialysis access circuit, or the patient reaches a censored event as deﬁned <em>a priori </em>in the study protocol. This period includes all intervening interventions (surgical or endovascular) designed to maintain the functionality of dialysis vascular access.</span></td> </tr> <tr> <td class="subtitle1_single">Post-intervention<sup>¶</sup> cumulative patency*</td> </tr> <tr> <td class="indent1">The interval of time <span style="font-size: 11pt; font-family: 'Calibri',sans-serif;">from the index IDBD intervention until the access is abandoned, including intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of a patent access, the patient reaches a censoring event as deﬁned <em>a priori </em>in the study protocol, or study end. </span></td> </tr> </tbody></table></div><div class="graphic_footnotes">AV: arteriovenous; IDBD: intervention, drug, biologic, device.<br/>* The term secondary patency has also been used in this context; however, this term has been misused in the literature, which makes it a confusing term that we prefer not to use. <br/>¶ Intervention: Any surgical or endovascular manipulation of the access to maintain or reestablish its functionality.</div><div class="graphic_reference">Adapted with permission from: Shenoy S, Allon M, Beathard G, et al. Clinical trial end points for hemodialysis vascular access: Background, rationale, and definitions. Clin J Am Soc Nephrol 2018; 13:490. Copyright © 2018 American Society of Nephrology.</div><div id="graphicVersion">Graphic 70111 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
